Pfizer (PFE) Total Current Liabilities (2009 - 2026)

Pfizer (PFE) has reported Total Current Liabilities for 18 consecutive years, with $32.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 13.47% year-over-year to $32.6 billion in Q2 2026; TTM through Jun 2026 was $32.6 billion, a 13.47% decrease from a year earlier, with the FY2025 full-year figure at $37.0 billion, down 13.98% from the prior year.
• Total Current Liabilities was $32.6 billion for Q2 2026 at Pfizer, down from $34.3 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $47.8 billion in Q4 2023 and troughed at $5.2 billion in Q3 2022.
• A 5-year average of $35.8 billion and a median of $37.4 billion in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 87.48% in 2022 and jumped 606.41% in 2024, its largest moves.
• Over 5 years, Total Current Liabilities stood at $42.1 billion in 2022, then climbed by 13.42% to $47.8 billion in 2023, then decreased by 10.04% to $43.0 billion in 2024, then dropped by 13.98% to $37.0 billion in 2025, then declined by 11.73% to $32.6 billion in 2026.
• The last three Total Current Liabilities figures came in at $32.6 billion (Q2 2026), $34.3 billion (Q1 2026), and $37.0 billion (Q4 2025), per Business Quant data.